| Company Name: |
RuiErKang Pharmaceuticals, Inc.
|
| Tel: |
2921645477 |
| Email: |
2921645477@qq.com |
| Products Intro: |
Product Name:N-[2-(3-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-beta-alanine ethyl ester
CAS:1394854-51-3
Purity:98% Package:5g;10g;100g
|
| Company Name: |
Shanghai Balmxy Pharmaceutical Co., Ltd
|
| Tel: |
021-24206007 13764915196 |
| Email: |
sales@balmxy.com |
| Products Intro: |
Product Name:Gsk j5
CAS:1394854-51-3
Purity:98%+ Package:5g;25g;100g;500g;1kg;5kg;25kg;100kg Remarks:BX50854
|
- GSK J5
-
- $39.00 / 1mg
-
2024-11-19
- CAS:1394854-51-3
- Min. Order:
- Purity: 100%
- Supply Ability: 10g
|
| Product Name: | GSK J5 | | Synonyms: | GSK J5;GSK-J5;N-[2-(3-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-beta-alanine ethyl ester;Ethyl N-[2-(3-pyridinyl)-6-(1,2,4,5-tetrahydro-3h-3-benzazepin-3- Yl)-4-pyrimidinyl]-β-alaninate;N-[2-(3-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-alanine ethyl ester;CS-2752;β-Alanine, N-[2-(3-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-, ethyl ester;GSK-J5|||GSKJ5 | | CAS: | 1394854-51-3 | | MF: | C24H27N5O2 | | MW: | 417.50348 | | EINECS: | | | Product Categories: | | | Mol File: | 1394854-51-3.mol |  |
| | GSK J5 Chemical Properties |
| Boiling point | 581.2±50.0 °C(Predicted) | | density | 1.216±0.06 g/cm3(Predicted) | | storage temp. | Store at RT | | solubility | insoluble in H2O; ≥17.3 mg/mL in EtOH with ultrasonic; ≥19.5 mg/mL in DMSO | | form | solid | | pka | 5.87±0.10(Predicted) | | color | Off-white |
| | GSK J5 Usage And Synthesis |
| Uses | GSK J5 is a inactive isomer of GSK J4 (G797555), which is a cell permeable inhibitor of the histone demethylase JMJD3/UTX. | | Biological Activity | gsk j5 is an inactive isomer of gsk j4 and a cell-permeable ester derivative of inactive control gsk j2. lysine-specific demethylase 6b (kdm6b), also known as jumonji domain-containing protein d3 (jmjd3), was overexpressed in patients with aml and these patients have a poor prognosis. kdm6b-specific pharmacological inhibitor gsk-j4 had a significant anti-proliferative effect in aml cell lines and freshly isolated bm monocytes (mncs) from aml patients, while h3k27me3 levels were also increasing. gsk-j4 also caused apoptosis and cell cycle arrest in vitro, and reduced tumor burden in vivo in aml xenograft mouse models. it is worth noting that injection of gsk-j4 attenuated disease progression in a human aml xenograft mouse model. treatment with gsk-j4 mainly resulted in downregulation of dna replication and cell cycle-related pathways, and prevents the expression of hox, a key cancer gene. chip-qpcr verified the increased h3k27me3 enrichment in the hox gene transcription initiation site [1].[1]. li y, zhang m, sheng m, zhang p, chen z, xing w, bai j, cheng t, yang fc, zhou y. therapeutic potential of gsk-j4, a histone demethylase kdm6b/jmjd3 inhibitor, for acute myeloid leukemia. j cancer res clin oncol. 2018 jun;144(6):1065-1077. doi: 10.1007/s00432-018-2631-7. epub 2018 mar 28. pubmed pmid: 29594337; pubmed central pmcid: pmc5948279. |
| | GSK J5 Preparation Products And Raw materials |
|